Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSPO | P30536 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9931971 | 0.91 | LMNA (0.50) | LMNANPSR1PTPN1ALDH1A1TP53 | |
| SCHEMBL7985518 | 0.89 | LMNA (0.51) | LMNANPSR1PTPN1ALDH1A1TP53 | |
| SCHEMBL12501297 | 0.83 | LMNA (0.46) | LMNANPSR1PTPN1GABRA1GABRB2 | |
| SCHEMBL7978939 | 0.82 | LMNA (0.49) | LMNANPSR1ALDH1A1TP53MAPT | |
| SCHEMBL8061230 | 0.82 | LMNA (0.44) | LMNANPSR1PTPN1GABRA1GABRB2 | |
| SCHEMBL27320089 | 0.82 | TSHR (0.47) | LMNANPSR1PTPN1GABRA1GABRB2 | |
| SCHEMBL1955058 | 0.82 | LMNA (0.44) | LMNANPSR1PTPN1GABRA1GABRB2 | |
| SCHEMBL5590843 | 0.79 | NPSR1 (0.47) | LMNANPSR1PTPN1ALDH1A1TP53 | |
| SCHEMBL30172661 | 0.79 | PTPN1 (0.43) | LMNANPSR1PTPN1GABRA1GABRB2 | |
| SCHEMBL4974968 | 0.79 | PTPN1 (0.43) | LMNANPSR1PTPN1GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000004775-A1 | MOLLUSCICIDAL COMPOSITION | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2000-02-03 | — | — | WO | claimed |
| EP-2585073-B1 | ANTIVIRAL COMPOUNDS | PROSETTA ANTIVIRAL INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-8785434-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8759336-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2585073-A1 | ANTIVIRAL COMPOUNDS | Prostetta Antiviral Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| EP-2550261-A2 | PYRIDAZINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | BASF SE (DE) | 2013-01-30 | — | — | EP | disclosed |
| WO-2012125983-A1 | ANTIVIRAL TREATMENTS | PROSETTA ANTIVIRAL INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120238543-A1 | Antiviral Compounds | Prosetta Antiviral, Inc. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120157435-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011137447-A1 | ANTIVIRAL COMPOUNDS | PROSTETTA ANTIVIRAL INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011117213-A1 | PYRIDAZINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | BASF SE (DE) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011117806-A2 | PYRIDAZINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | BASF SE (DE) | 2011-09-29 | — | — | WO | disclosed |
| WO-2000004775-A1 | MOLLUSCICIDAL COMPOSITION | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238543-A1 | Antiviral Compounds | MAVS, EIF2AK2, IRF3 | LMNA 3112/4885NPSR1 3707/4885PTPN1 2319/4885 |
| US-20120157435-A1 | Antiviral Compounds | MAVS, ZC3HAV1, EIF2AK2 | LMNA 1442/4885NPSR1 3601/4885PTPN1 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.